Home Study Modules

Course Details (Activity Announcement): View File (LAIS01 Activity Announcement)

Pharmacist Administration of Long-Acting Injectable Maintenance Medications: Understanding the Regulations

This module reviews the regulations and policies for pharmacist administration of long-acting maintenance medications.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Describe the current regulations for pharmacist administration of long-acting injectable medications in Maryland.
2. Outline the training requirements for pharmacist administration of long-acting injectable medications in the State of Maryland.
3. Describe examples of documentation utilized in pharmacist administration of long-acting injectable medications.
4. Review example policies utilized in pharmacist administration of long-acting injectable medications.

UAN: 0025-0000-23-065-H03-P
CE Credit: 1.0 Contact Hours
Activity Type: Knowledge
Initial Release: May 22, 2023
Expiration Date: May 22, 2024

Instructor:
Megan Ehret, PharmD, MS, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. None of the other planners for this activity have any financial relationships to disclose. All financial relationships have been mitigated.

---

Maryland Pharmacist Opioid Use Disorder (OUD) LAI Administration Training

This module reviews the management of a patient population with opioid use disorder and the long-acting injectable medications utilized in the treatment of opioid use disorder.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Describe the management of a patient population with opioid use disorder, including current treatment guidelines.
2. List current long-acting injectable medication(s) utilized in the treatment of opioid use disorder.
3. Outline pharmacokinetics, significant drug interactions, warnings/precautions, and adverse effects for long-acting injectable medication(s) for the treatment of opioid use disorder.
4. Describe the dosing and administration frequency of the long-acting injectable medication(s) for the treatment of opioid use disorder. 

UAN: 0025-0000-23-066-H01-P
CE Credit: 1.0 Contact Hours
Activity Type: Knowledge
Initial Release: May 22, 2023
Expiration Date: May 22, 2024

Instructor:
Bethany DiPaula, PharmD, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. DiPaula, presenter for this activity, has no financial relationships to disclose. Dr. Megan Ehret, planner for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. None of the other planners for this activity have any financial relationships to disclose. All financial relationships have been mitigated.  

---

Long-Acting Injectable Medications for the Treatment of Schizophrenia and Bipolar Disorder

This module reviews the management of a patient population with opioid use disorder and the long-acting injectable medications utilized in the treatment of schizophrenia and bipolar disorder.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Describe the management of a patient population with schizophrenia or bipolar disorder, including treatment guidelines.
2. List the current long-acting injectable medications utilized in the treatment of schizophrenia or bipolar disorder.
3. Outline the pharmacokinetic, significant drug interactions, warnings/precautions, and adverse effects for the long-acting injectable medications for the treatment of schizophrenia or bipolar disorder.
4. Describe the dosing and administration frequency of the long-acting injectable medications for the treatment of schizophrenia or bipolar disorder. 

UAN: 0025-0000-23-067-H01-P
CE Credit: 2.0 Contact Hours
Activity Type: Knowledge
Initial Release: May 22, 2023
Expiration Date: May 22, 2024

Instructor:
Megan Ehret, PharmD, MS, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. None of the other planners for this activity have any financial relationships to disclose. All financial relationships have been mitigated.  

---

Long-acting Antiretroviral Therapies

This module reviews the management of a patient population with opioid use disorder and the long-acting injectable medications utilized in the treatment of HIV.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Describe the management of a patient population with HIV, including treatment guidelines.
2. List the current long-acting injectable medications utilized in the treatment/prevention of HIV.
3. Outline the pharmacokinetic, significant drug interactions, warnings/precautions, and adverse effects for the long-acting injectable medications for the treatment/prevention of HIV.
4. Describe the dosing and administration frequency of the long-acting injectable medications for the treatment/prevention of HIV. 

UAN: 0025-0000-23-068-H02-P
CE Credit: 1.0 Contact Hours
Activity Type: Knowledge
Initial Release: May 22, 2023
Expiration Date: May 22, 2024

Instructor:
Neha Pandit, PharmD, BCPS
Professor
University of Maryland School of Pharmacy
Dr. Pandit, author and presenter for this activity, has received a research grant from Thera Technologies. Dr. Megan Ehret, planner for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. None of the other planners for this activity have any financial relationships to disclose. All financial relationships have been mitigated. 

---

Pharmacologic Interventions for Transgender/Non-binary Adolescents and Adults

This module reviews the goals of transgender care and the long-acting injectable medications utilized for puberty suppression and GAHT.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Recognize the goals of transgender care management at different transitional stages.
2. Classify which pharmacologic agents are indicated for use at different stages, particularly long-acting injectable formulations.
3. Contrast the different dosing and administration preparations for long-acting injectable puberty suppression and GAHT.
4. Identify important monitoring parameters and medication related variables for a given pharmacologic intervention.

UAN: 0025-0000-23-069-H01-P
CE Credit: 1.0 Contact Hours
Activity Type: Knowledge
Initial Release: May 22, 2023
Expiration Date: May 22, 2024

Instructor:
Amy Kruger Howard, MS, PharmD
Pediatric Clinical Pharmacist
University of Maryland School of Pharmacy
Dr. Amy Kruger Howard, presenter for this activity, has no financial relationships to disclose. Dr. Megan Ehret, planner for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. None of the other planners for this activity have any financial relationships to disclose. All financial relationships have been mitigated.  

---

Long-Acting Maintenance Medication Administration Techniques

This module reviews the various injection techniques and locations for long acting injectables.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Identify routes of administration for long-acting maintenance injections administered by a pharmacist.
2. Describe appropriate injection technique for intramuscular and subcutaneous injections.
3. Describe how to give a medication via z-track administration.
4. Review volumes of injection for various injection routes.

UAN: 0025-0000-23-070-H99-P
CE Credit: 1.0 Contact Hours
Activity Type: Knowledge
Initial Release: May 22, 2023
Expiration Date: May 22, 2024

Instructor:
Megan Ehret, PharmD, MS, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. None of the other planners for this activity have any financial relationships to disclose. All financial relationships have been mitigated.  

---

Long-Acting Maintenance Medication Preparation Techniques

This module reviews the various preparation techniques for long acting injectables.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Describe the preparation and storage of long-acting maintenance injectable medications.
2. Identify resources to review the preparation and administration prior to providing injections.

UAN: 0025-0000-23-109-H01-P
CE Credit: 0.5 Contact Hours
Activity Type: Knowledge
Initial Release: September 28, 2023
Expiration Date: September 28, 2024

Instructor:
Megan Ehret, PharmD, MS, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. None of the other planners for this activity have any financial relationships to disclose. All financial relationships have been mitigated.

---

Criteria for Successful Completion for Home Study Modules
To successfully complete a module, learners must complete all activity components including the audiovisual presentations, active learning exercises, a post-test, and activity evaluation. Participants must receive a score of at least 70% on each post-test to receive credit. A post-test may be taken up to three (3) times. A link to the evaluation will be available once learners have successfully completed all other course segments. Statements of CE Credit will be available electronically via CPE Monitor within sixty (60) days of completion of the activity.

The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. No additional financial support was received for these activities.

Long-Acting Maintenance Injection Administration Learning Lab

Course Details (Activity Announcement): View File (LAIS02_L Activity Announcement)

Module Description/What to Expect During the Learning Lab:
During this live, in-person session, learners will have the opportunity to practice IM deltoid, IM gluteal and Subcutaneous injections. During this session, learners will complete an injection assessment using simulation models.

Learners will sign-up for a learning lab session using an online form; additional activity dates will be scheduled throughout the year.

Learning Lab Location:
University of Maryland School of Pharmacy
20 N. Pine Street, Baltimore, MD 21201  

Activity Schedule
The following dates/time have been scheduled for Learning Lab sessions.

• Tuesday, September 17, 2024, 10:00 - 11:00 am
• Tuesday, September 17, 2024, 11:00 am - 12:00 pm
• Tuesday, November 12, 2024, 10:00 - 11:00 am
• Tuesday, November 12, 2024, 11:00 am - 12:00 pm
• Tuesday, January 14, 2025, 10:00 - 11:00 am
• Tuesday, January 14, 2025, 11:00 am - 12:00 pm
• Tuesday, March 11, 2025, 10:00 - 11:00 am
• Tuesday, March 11, 2025, 11:00 am - 12:00 pm
• Tuesday, May 13, 2025, 10:00 - 11:00 am
• Tuesday, May 13, 2025, 11:00 am - 12:00 pm

Registrants are required to sign-up at least two weeks prior to the Learning Lab date using the online form. The link to this form will be sent via email.

Learning Objectives:
At the completion of this activity, learners should be able to:

1. Identify landmarks for the deltoid, abdomen, and gluteal muscles prior to administration of long-acting injectable medications.
2. Demonstrate appropriate techniques for intramuscular and subcutaneous injection.

UAN: 0025-0000-23-100-L04-P
CE Credit: 1.0 Contact Hours
Activity Type: Application

Instructors & Disclosures
Megan Ehret, PharmD, MS, BCPP
Professor; Co-Director of the Mental Health Program
University of Maryland School of Pharmacy

Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. All financial relationships have been mitigated.

None of the other planning committee members have any financial relationships to disclose.

Prerequisites:
Participants must be have completed the following home study modules prior to participating in a Learning Lab session:

• Pharmacist Administration of Long-Acting Injectable Maintenance Medications: Understanding the Regulations
• Maryland Pharmacist Opioid Use Disorder (OUD) LAI Administration Training
• Long-Acting Injectable Medications for the Treatment of Schizophrenia and Bipolar Disorder
• Long-acting Antiretroviral Therapies
• Pharmacologic Interventions for Transgender/Non-binary Adolescents and Adults
• Long-Acting Maintenance Medication Administration Techniques
• Long-Acting Maintenance Medication Preparation Techniques

Completion Standards for the Learning Lab:
To successfully complete this activity, learners must complete an IM deltoid, IM gluteal, and subcutaneous injection on a simulation model per the injection rubric. Additionally, learners are required to submit an activity evaluation. The link to the activity evaluation will be sent via email after the Learning Lab.

The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. No additional financial support was received for these activities.

 

Technology Requirements

Home Study

Unless otherwise noted in the course materials, the following are required to access online courses: A computer or mobile device with a stable internet connection and the ability to view and update Microsoft Word® and PowerPoint® documents.

Supported Internet Browsers	Windows Internet Explorer version 11 and above Chrome 43 and above Firefox 4.0 (or later) MacOS Safari 13 and above Chrome 43 and above
Minimum Memory	8 GB (or more)
Minimum Storage	6 GB (or more)
Minimum Processor	PC: 2 GHz or faster Intel processor MacOS: Multi-core Intel processor
Minimum Internet Speeds	High speed internet connection
Other	Participants must be able to play audio (either through speakers or headphones) as well as ability to open PDF files and view and edit Word, and PPT documents.

Learning Lab

The learning lab is a live, in-person activity; there are no technology requirements.

Privacy and Confidentiality: The University of Maryland School of Pharmacy is committed to protecting the privacy of our learners. All registrants are protected under The Family Educational Rights and Privacy Act (20 U.S.C. § 1232g; 34 CFR Part 99) (FERPA). The UMB Policy on Confidentiality and Disclosure of Student Records can be found at: https://www.umaryland.edu/policies-and-procedures/library/academic-affairs/policies/iii-630a.php

In order to submit your continuing education credit record to National Association of Boards of Pharmacy (NABP) CPE Monitor, we must collect personal information including, but not limited to, name, NABP ID, and date of birth. Additionally, Maryland-licensed pharmacists seeking a Contraceptive Prescribing credential must allow for submission of their activity completion record to the Maryland Board of Pharmacy.

Copyright: Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of and have been prepared by the University of Maryland Baltimore or have been granted permission for use by the copyright owner.  No portion of this module may be reproduced or transmitted without written permission.  All rights reserved.

Statement on the use of images/videos:  
SMI Adviser, a center for excellence for treatment of serious mental illness, is funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) and administered by the American Psychiatric Association (APA).   SMI Adviser has created a series of videos on the proper preparation and administration of long-acting injectable medications.   They have granted approval for use of their videos in our training program.   

Use of Trade Names:  The trade names of the drugs and delivery systems in this module are for the purpose of product identification only. This activity does not intend to imply endorsement for any commercial products discussed.

Refund Policy

• A refund, less a $75 administration fee, will be made if cancellations are made within 15 days of purchase. Other restrictions may apply.
• Refund requests must be submitted in writing to CEHelp@rx.umaryland.edu.
• Refunds are not available in the following circumstances:
  • A learner has logged into a course or series;
  • A learner has launched course materials;
  • Course materials have been shipped; or
  • Request is made after 15 days of the ordering date.
• Course registrations are non-transferrable.

Questions?  Review the Frequently Asked Questions page.  Can't find what you are looking for?  Contact Customer Service at CEHelp@rx.umaryland.edu

or 410-706-3381.